middle.news
Percheron Advances HMBD-002 with WHO Naming and $2.2M Capital Boost
8:29am on Friday 31st of July, 2026 AEST
•
Biotechnology
Read Story
Percheron Advances HMBD-002 with WHO Naming and $2.2M Capital Boost
8:29am on Friday 31st of July, 2026 AEST
Key Points
HMBD-002 granted provisional WHO international non-proprietary name
New drug batch manufactured for clinical trial starting September 2026
Entitlement offer raised $2.2 million to advance HMBD-002 development
Positive clinical and preclinical data presented at AACR and ASCO conferences
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE